Staphylococcus aureus meningitis with intermediate sensitivity to glycopeptides: Therapeutic indications;Méningite à Staphylococcus aureus de sensibilité intermédiaire aux glycopeptides: Implications thérapeutiques

Presse Medicale

Volumn 32, Issue 5, 2003, Pages 217-220

  Pofelski, J ^a   Pavese, P ^a   Brion, J P ^a   Marrakchi, C ^a   Gay, E ^a   Recule, C ^a   Stahl, J P ^a  

^a UNIV GRENOBLE ALPES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPEPTIDE;

ADULT; ARTICLE; BACTERIAL MENINGITIS; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; HUMAN; LABORATORY TEST; MALE; STAPHYLOCOCCUS AUREUS; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0037425805     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Ogfuri T, Tenover FC. Meticillin-resistant Staphylococcus aureus clinical strain with reduced vancomycine susceptibility. J Antimicrob Chemother 1997; 40: 135-6.
2. Reverdy ME, Jarraud S, Bobin-Dubreux S et al. Incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in two French hospitals. Clin Microbiol Infect 2001; 7: 267-72.
3. Allouch PY, Astragneau P, Aubry-Damon H et al. Le point sur la situation épidémiologique de Staphylococcus aureus de sensibilité diminuée aux glycopeptides en France. BEH 2000; 23: 97-9.
4. Fridkin SK. Vancomycine-intermediate and resistant Staphylococcus aureus: what the infectious specialist needs to know. Clin Infect Dis 2001; 32: 108-15.
5. Ploy MC, Grélaud C, Martin CL de Lumley, Denis F. First clinical isolate of vancomycine-intermediate Staphylococcus aureus in a French hospital. Lancet 1998; 351: 1212.
6. Trakulsomboon S, Danchaivijitr S, Rongrungruang Y et al. First report of Meticillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Vancomycine in Thailand. J Clin Microbiol 2001; 39: 591-5.
7. Kim M-N, Pai C H, Woo JH, Ryu JS, Hiramatsu K. Vancomycine-Intermediate Staphylococcus aureus in Korea. J Clin Microbiol. 2000; 38: 3879-81.
8. Smith TL, Pearson ML, Wilcox KR et al. Emergence of vancomycine resistance in Staphylococcus aureus. N Engl J Med 1999; 340: 493-501.
9. Rotun SS, McMath V, Schoonmaker DJ et al. Staphylococcus aureus with reduced susceptibility to vancomycine isolated from a patient with fatal bacteriemia. Emerging Infect Dis 1999; 5: 147-9.
10. Centers for Disease Control and Prevention. Staphylococcus with reduced susceptibility to vancomycin: Illinois, 1999. Morb Mortal Wkly Rep 2000; 351: 1165-7.
11. Guerin F, Buu-Hoï A, Mainardl LJ et al. Outbreak of Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Glycopeptides in a Parisian Hospital. J Clin Microbiol 2000; 38: 2985-8.
12. Chesnau O, Morvan A, El Solh N. Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals. J Antimicrob Chemother 2000; 45: 888-890.